Peter Raubenheimer

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Tali Cukierman‐Yaffe, Hertzel C. Gerstein, Helen M. Colhoun et al. · The Lancet Neurology · 2020 · 270 citations

Medicine, Pharmacology, Pharmacotherapy +14

A Choline-Deficient Diet Exacerbates Fatty Liver but Attenuates Insulin Resistance and Glucose Intolerance in Mice Fed a High-Fat Diet

Peter Raubenheimer, Moffat Nyirenda, Brian R. Walker · Diabetes · 2006 · 198 citations · Full text

Medicine, Endocrinology, Nutritional Sciences +17

Design and baseline characteristics of participants in the <scp>R</scp> esearching cardiovascular <scp>E</scp> vents with a <scp>W</scp> eekly <scp>IN</scp> cretin in <scp>D</scp> iabetes ( <scp>REWIND</scp> ) trial on the cardiovascular effects of dulaglutide

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · Diabetes Obesity and Metabolism · 2017 · 186 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17